00:13 , Nov 6, 2018 |  BC Extra  |  Preclinical News

Foghorn co-founder shows chromatin remodeling inhibition could treat sarcoma

Dana-Farber Cancer Institute researchers, including Foghorn Therapeutics Inc. (Cambridge, Mass.) co-founder Cigall Kadoch, and colleagues suggested inhibitors of the chromatin remodeling non-canonical BAF complex (ncBAF) could help treat sarcomas. Three SWI/SNF complexes with distinct but...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Bromodomain containing 9 (BRD9)

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified two naphthyridinone-based BRD9 inhibitors that could help treat AML. Fragment screening, chemical synthesis on hits and in vitro assays identified two naphthyridinone analogs...